ARECOR THERAPEUTICS PLC (AREC) — Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the ARECOR THERAPEUTICS PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company will review all questions submitted today and publish responses where it is appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Sarah Howe, CEO. Good afternoon. Great. Thank you, Lily. Good afternoon, everybody. Thank you for joining us today. So we'll be talking through ARECOR's full results for the year ending 12/31/2022. So I draw your attention to our customary legal notice. So today, it's myself. I've got Sarah Howell. I'm the CEO of ARECOR, and I'm joined by Susan Louth, our CFO. But just by way of summary of ARECOR for those of you joining us for the first time today and and for those joining us again, thank you. And just a recap, really. So we're very much focused on transforming patient care by enhancing existing therapeutic medicines so that they're safer, more effective, and convenient to use for patients and the end users. And we do this by leveraging our innovative and proprietary formulation technology platform, ARISTAT. And we use this platform to enhance the properties of those existing therapeutic products or medicines and very much focused on improving performance and ultimately patient outcomes and quality of life. And as a, technology platform company, intellectual property is absolutely key to us, and we have very broad and robust IP protect...